Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PFE (Pfizer) How high will it go? -- Ignore unavailable to you. Want to Upgrade?

To: Anthony Wong who wrote (6209)	11/5/1998 9:19:00 PM
From: BigKNY3	Read Replies (1) \| Respond to of 9523

PFEr Alert: 11/05/98 Expect an exciting day on Friday with the annual PFE R&D analyst meeting.Meeting highlights will include the latest news on the PFE pipeline and operations including Celebrex, inhaled insulin, Trovan and, of course, Viagra. Note the meeting starts prior to the market opening. From the WWW.Pfizer.com Website: When is Pfizer's next analyst meeting? Pfizer's next analyst meeting is Friday, November 6, 9:00 a.m., at Pfizer headquarters in New York (235 East 42nd St.). William C. Steere, Jr., Chairman and Chief Executive Officer, will host the meeting; David Shedlarz, Senior Vice President and Chief Financial Officer, will review Pfizer's operating results; and Dr. John Niblack, Executive Vice President, and Dr. George Milne, Vice President and President--Central Research, will discuss our new product pipeline. Have PFun! BigKNY3

To: Anthony Wong who wrote (6209)	11/5/1998 9:29:00 PM
From: BigKNY3	Read Replies (2) \| Respond to of 9523

Pfizer Files for FDA Approval of Migraine Drug Eletriptan Bloomberg News November 5, 1998, 3:43 p.m. PT Pfizer Files for FDA Approval of Migraine Drug Eletriptan New York, Nov. 5 (Bloomberg) -- Pfizer Inc., the No. 4 U.S. drugmaker, said it has filed for U.S. approval of a new migraine medicine, one of three products it could introduce in 1999. The New York-based drugmaker filed an application late last month with the U.S. Food and Drug Administration for eletriptan, a migraine medicine, said Marian Caprino, a company spokeswoman. Review of the application may take a year. Pfizer's other two possible 1999 drug introductions are Tikosyn, for an irregular heart rhythm known as atrial fibrillation, and a potential blockbuster arthritis medicine, Celebrex. Pfizer will market this drug through an agreement with Monsanto Co., which developed the drug. Celebrex treats pain and swelling without irritating the lining of the stomach, as does existing painkillers such as American Home Products Corp.'s Advil. Pfizer will review its drug research at an analysts' meeting in New York tomorrow. It shares rose 1 3/8 to 107 3/8 today. Sales of Celebrex could reach $500 million in its first year on the market, according to some estimates. Tikosyn could have 1999 sales of $75 million, according to ABN Amro, and eletriptan, of $30 million.